Eli Lilly Weight-Loss Drug India: If you are struggling with obesity and diabetes, then you can get relief soon. America’s leading drug company Eli Lily has launched a drug called Maunzaro for obesity and type 2 diabetes patients in India. This drug has been available after receiving approval from the drug regulator of India. The price of 5 Mg Vial of Maunzaro has been fixed at Rs 4,375 and the price of 2.5 Mg Vial has been fixed at Rs 3,500. In India, this drug has been priced especially with the objective that more and more people can avail this latest treatment. It is noteworthy that about 10.1 crore people in India are affected by diabetes.
The Supreme Court acquitted 6 in the riots case after Godhra, said-‘It is necessary to ensure that no eyewitness is guilty in the dungs’
The company has also told that this drug will be effective in improving metabolic health and weight loss. India, which is the most populous country in the world, is increasing the cases of obesity and diabetes. This drug is helpful in controlling blood sugar and reducing appetite.
How does the medicine work?
This medicine is consumed once a week, and it can cost from Rs 14,000 to Rs 17,500 per month as per the dose prescribed by the doctor. It is the first drug for obesity and type-2 diabetes that activates GIP and GLP-1 hormone receptors. This drug can provide a new and effective treatment, which can improve the metabolic health of patients. It is helpful in increasing insulin production in the body, reducing glucagon levels, improving insulin sensitivity and controlling appetite. In addition, it also helps in reducing the amount of body fat and controlling lipid use.
‘Whoever shows our Muslim brothers eye, he is a strict warning of Maharashtra Deputy CM Ajit Pawar amid Aurangzeb controversy
Why is the price low in India
The company claims that this drug activates both GIP (glucose-deepent insulinotropic polypeptide) and GLP-1 (Glucagon-Like Peptide-1) hormone receptors. The purpose of keeping the price of this medicine low in India is to ensure its access to more and more people. There has been a significant increase in demand for GLP-1 category drugs for management of diabetes and obesity globally, causing its market to billions of dollars.
The patent of Semaglutide, the major drug of this class, will end in March next year. After this, Indian companies like Mankind Pharma, Alkem Labs and Dr Reddy’s Laboratories are planning to bring its generic versions to the market. The demand for these drugs is increasing for the reason because they provide significant assistance in weight loss. Obesity can cause more than 200 health problems. By 2023, about 100 million people in India were obese.
Did Shashi Tharoor walk on the BJP’s path? BJP leader shared picture with Congress MP
10 million people suffering from obesity and diabetes
Elli Lily said in an announcement that about 100 million people in India are affected by diabetes and obesity. Obesity is not only an important risk factor of diabetes, but it is also related to more than 200 health problems, including high blood pressure, coronary heart disease, and obstructive sleep apnea.
At what age should the blood sugar level be?
The normal level of fasting blood sugar is between 80 to 100 mg/DL. If this level is between 100 to 125 mg/DL, it is classified as predeabitates. When it is more than 126 mg/DL, the person is considered diabetic. HBA1C testing is done to confirm this condition, which assesses blood sugar levels in the last three months. This test determines whether the person has diabetes or not. People between the ages of 40 to 60, especially, should be cautious about the symptoms of predeabitarianism. If the level of HBA1C is between 5.7% to 6.4%, the person may be a victim of predeed, and is considered to be affected by diabetes when more than this.